the hearts & minds
Leadership with direction, purpose and lifetimes of experience that encompass all aspects of pharmaceutical development through commercialization.
William Moore, PhD PRESIDENT & CHIEF EXECUTIVE OFFICER25 years of innovative pharmaceutical R&D leadership
A business and scientific leader in pharmaceutical and biotechnology R&D, Dr. Moore has devoted his 25-year career to championing new chemical entities from discovery to the clinic (the pharmaceutical industry ‘Valley of Death’) for the treatment of asthma, osteoporosis, inflammatory diseases, and particularly oncology. Dr. Moore has held key positions such as Chief Executive Officer, President, Director and Chief Scientific Officer for companies that include Arris, Axys, Locus Pharmaceuticals, and most recently, Innocrin Pharmaceuticals (2014-2017). Dr. Moore’s responsibilities have included the evolution of corporate strategy, business development, management of external alliances, intellectual property, fundraising and all aspects of R&D and technology innovation.
Dr. Moore has a BS degree in chemistry from Southeastern Massachusetts University, a PhD degree in chemistry from Brown University and, prior to joining the pharmaceutical industry, was a Winston Fellow and Assistant Professor in Biochemistry at Cornell University Medical College.
George Cox, PhD, JD CHIEF LEGAL OFFICER & CORPORATE SECRETARY30 years of cutting edge scientific and legal expertise
Dr. George Cox brings more than 30 years of combined science and legal experience to Propella Therapeutics. Prior to joining Propella, Dr. Cox was in private practice at IP & Business Law Counseling, LLC, Miles & Stockbridge PC, and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Before attending law school, he enjoyed a career as a biomedical scientist and medical school professor at the National Cancer Institute and the Uniformed Services University of the Health Sciences. He’s authored more than 70 publications in diverse scientific disciplines including pharmacology, immunology, biochemistry, and cell and molecular biology.
Dr. Cox earned his BA degree in chemistry and zoology from Ohio Wesleyan University, his PhD degree in pharmacology from The Ohio State University College of Medicine, and his JD degree from The American University Washington College of Law. Dr. Cox also serves on the Board of Directors of Luminary Therapeutics.
Michael Billard, MS VICE PRESIDENT, OPERATIONS20 years of solution-driven management experience
Mike is a leader skilled in operations & project management, problem-solving, cross-functional team building, and change management. He led a group of project managers supporting contract development and manufacturing of biopharmaceuticals in his position as Vice President, Project Management for Paragon Bioservices. Previously, Mike served as Executive Director, Corporate Project Management for DSM Nutritional Products (formerly Martek Biosciences) where he established and ran a Project Management Office primarily responsible for new product development and operations projects. He was also instrumental in the integrations of both Martek Biosciences and Ocean Nutrition Canada into DSM following their acquisitions. Prior to joining DSM, Mike was a project manager in roles of increasing responsibility with MedImmune, Inc. and Baxter Healthcare Corporation.
Mike holds a BS in Chemistry from Illinois State University and a MS in Biotechnology from The Johns Hopkins University.
Christopher Prue, MBA VICE PRESIDENT, REGULATORY AFFAIRS30 years of insightful science and regulatory experience
Chris brings more than 39 years of combined science and regulatory experience to Propella Therapeutics. Prior to joining Propella, Chris has held roles of increasing responsibility in Regulatory Affairs, Quality Assurance and Pharmacovigilance starting with the Upjohn Company, progressing to Glaxo Inc. and Purdue Pharma LP as well as in small Biotech start-ups. His therapeutic area experience includes metabolism and endocrine, cardiovascular, analgesia, anesthesia, dermatology, and CNS. His product development experience includes solid oral dosage forms, soft gelatin capsules, liquids, creams, ointments, aerosol delivery systems, sterile products, therapeutic proteins and cell-based therapies.
Chris hold a BS in Pharmacy from Purdue University and an MBA from Western Michigan University.
Matthew Sharp, PhD VICE PRESIDENT, PRODUCT DEVELOPMENT25 years of successful pharmaceutical product development
Dr. Matt Sharp brings more than 25 years of pharmaceutical product development experience to Propella Therapeutics. Prior to joining Propella he was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Innocrin Pharmaceuticals. Previously, he held a number of positions of increasing responsibility with GlaxoSmithKline (GSK), most recently serving as U.S. Head of Process Robustness and 2nd Generation, Active Pharmaceutical Ingredients (APIs). In these roles he was responsible for the development and manufacture of APIs as well as finished drug products. He has extensive experience in the manufacturing of drug products, research and development, process development, cGMP manufacturing, analytical development and quality systems.
In preparation for his pharmaceutical career, Matt received a BSc degree in Chemistry from Sheffield City (England) Polytech, a MSc in Organic Chemistry from the University of Waterloo (Canada), a PhD in Organic Chemistry from the University of California, Irvine, and then trained as postdoctoral research fellow at the University of California, Berkeley.
Tim Warneke, MS VICE PRESIDENT, CLINICAL OPERATIONS30 years of results-focused clinical development
Tim Warneke has more than 30 years of pharmaceutical development experience in clinical operations. These experiences range across large (Ciba-Geigy and Abbott Laboratories) to mid-size (King Pharmaceuticals) pharmaceutical companies and the world’s largest contract research organization (Quintiles, now IQVIA). Tim has leveraged his expert knowledge of the Code of Federal Regulations, ICH Guidelines, Good Clinical Practice to provide operational excellence in support of numerous INDs and NDAs throughout his career. Operationally focused, he has been responsible for clinical study conduct across all phases of pharmaceutical development from single-center studies to large multi-national clinical trials over a wide array of therapeutic areas. Tim began his career at Northwestern University in the Department of Community Health and Preventive Medicine coordinating the clinical activities of the landmark NHLBI funded CARDIA study from its initial year in 1983 to 1988.
Tim holds a BS in Education and MS in Exercise Physiology from Eastern Illinois University.